In addition, another research group reports only a modest improvement of locomotor activity without any effect on cognition or tau pathology in a transgenic AD model (Li et al., 2020) by using the same PD-1 checkpoint blockade approach (Baruch et al., 2016; Rosenzweig et al., 2019). Here, MAPT is linked to Alzheimer disease.